Anti-angiogenic compositions and methods of use

Details Anti-angiogenic compositions and methods of use Anti-angiogenic compositions and methods of use

2005-01-25

2005-01-25

Kumar, Shailendra (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S210030, C514S250000, C514S825000, C514S826000

Reexamination Certificate

active

06846841

ABSTRACT:
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

REFERENCES:
patent: 4542025 (1985-09-01), Tice et al.
patent: 5039521 (1991-08-01), Bolton et al.
patent: 5061724 (1991-10-01), Gertner
patent: 5171217 (1992-12-01), March et al.
patent: 5260066 (1993-11-01), Wood et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5511563 (1996-04-01), Diamond
patent: 5529786 (1996-06-01), Moore
patent: 5530003 (1996-06-01), Yanagawa
patent: 5560933 (1996-10-01), Soon-Shiong et al.
patent: 5583153 (1996-12-01), Brahn
patent: 5616608 (1997-04-01), Kinsella et al.
patent: 5626862 (1997-05-01), Brem et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5651986 (1997-07-01), Brem et al.
patent: 5667764 (1997-09-01), Kopia et al.
patent: 5719265 (1998-02-01), Mongelli et al.
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5801191 (1998-09-01), Bressi et al.
patent: 5811447 (1998-09-01), Kunz et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 5994341 (1999-11-01), Hunter et al.
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6171609 (2001-01-01), Kunz
patent: 6506411 (2003-01-01), Hunter et al.
patent: 6544544 (2003-04-01), Hunter et al.
patent: 3825374 (1990-02-01), None
patent: 616813 (1994-09-01), None
patent: 0470569 (1995-11-01), None
patent: 2693193 (1994-01-01), None
patent: WO 9110424 (1991-07-01), None
patent: WO 9111193 (1991-08-01), None
patent: WO 9212717 (1992-08-01), None
patent: WO 9318793 (1993-09-01), None
patent: WO 9323075 (1993-11-01), None
patent: WO 9503036 (1995-02-01), None
patent: WO 9948536 (1999-09-01), None
Brandwein et al., “Fatal Pulmonary Lipid Embolism Associated with Taxol Therapy,”The Mount Sinai Journal of Medicine 55(2):187-189, Mar. 1988.
Kamei et al., “Antitumor Effects of Angiogenesis Inhibitor TNP-470 in Rabbits Bearing VX-2 Carcinoma by Arterial Administration of Microspheres and Oil Solution,”The Journal of Pharmacology and Experimental Therapeutics 264(1):469-474, Jan. 1993.
Kato et al., “The Role of Embolization/Chemoembolization in the Treatment of Renal Cell Carcinoma,”Therapeutic Progress in Urological Cancers, Murphy and Khoury, eds., pp. 697-705, Alan R. Liss, Inc., NY, 1989.
Pazdur et al., “The taxoids: paclitaxel (Taxol®) and docetaxel®),”Cancer Treatment Reviews 19(4):351-386, Oct. 1993.
Weissleder et al., “A Drug System (PDH) for Interventional Radiology,”Investigative Radiology 28(12):1083-1089, Dec. 1993.
Asako et al., “Colchicine and Methotrexate Reduce Leukocyte Adherence and Emigration in Rat Mesenteric Venules,”Inflammation 16(1): 43, 1992.
Tang et al., “Regression of Collagen-Induced Arthritis with Taxol, A Microtubule Stabilizer,”Arthritis&Rheumatism 36(9, Suppl.): S45, Abstract No. 42, Sep. 1993.
Brahn et al., “Regression of Collagen-Induced Arthritis with Taxol, A Microtubule Stabilizer,”Arthritis&Rheumatism 37(6): 839-845, Jun. 1994.
Sloboda et al., “Studies of the Effect of Mitoxantrone on Adjuvant Induced Arthritis in Rats,”Clinical Immunology and Immunopathology 40: 236-243, 1986.
Oliver et al., “Suppression of Collagen-Induced Arthritis Using an Angiogenesis Inhibitor, AGM-1470, and a Microtubule Stabilizer, Taxol,”Cellular Immunology 157: 291-299, 1994.
Beckett et al., “Matrix Metalloproteinase Inhibitors in the Treatment of Rheumatoid Arthritis and Cancer,”Abstracts of Papers, 205thACS National Meeting, American Chemical Society, Denver, Colorado, Mar. 28-Apr. 2, 1993, Abstract No. 147, MEDI.
Grinstaff et al., “Intravenous Targeted Delivery of Taxol in Protein Microspheres,”American Chemical Society, 207thNational Meeting, Mar. 13-17, 1994, Abstract No. 91, MEDI.
Ratcliffe et al., “Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs,”J. Pharm. Pharmacol. 36: 431-436, 1984.
Ratcliffe et al., “Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthritic knee joints of rabbits,”J. Pharm. Pharamacol. 39: 290-295, 1987.
Hunneyball, I.M., “Intra-articular administration of drugs,”Pharmacy International: 118-122, May 1986.
Menkes, C.J., “Intraarticular Treatment of Osteoarthritis and Guidelines to its Assessment,”The Journal of Rheumatology 21: 74-76, 1994.
Mönkkönen et al., “Studies on liposome formulations for intra-articular delivery of clodronate,”Journal of Controlled Release 35: 145-154, 1995.
English Abstract of French Patent FR 2693193, Jan. 7, 1994.
English Abstract of German Patent DE 3825374, Feb. 1, 1990.
Dahlberg et al., “Intraarticular Injections of Hyaluronan in Patients with Cartilage Abnormalities and Knee Pain,”Arthritis&Rheumatism 37(4): 521-528, Apr. 1994.
Innocenti et al., “Plasma and Tissue Disposition of Paclitaxel (Taxol) After Intraperitoneal Administration in Mice,”Drug Metabolism and Disposition 23(7): 713-717, 1995.
Walter et al., “Interstitial Taxol Delivered from a Biodegradable Polymer Implant against Experimental Malignant Glioma,”Cancer Research 54: 2207-2212, Apr. 15, 1994.
Smith et al., “Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts,”Anti-Cancer Drugs 6: 717-726, 1995.
Burt et al., “Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid),”Cancer Letters 88: 73-79, 1995.
Pesenti et al., “Synthesis and biological activity of water soluble polymer-bound taxol derivatives,”Proceedings of the American Association for Cancer Research 36: Abstract No. 1824, Mar. 1995.
Durdunoo et al., “Taxol encapsulation in poly(ε-caprolactone) microspheres,”Cancer Chemother. Pharmacol. 36: 279-282, 1995.
Bartoli et al., “In vitro and in vivo antitumoral activity of free, and encapsulated taxol,”J. Microencapsulation 7(2): 191-197, 1990.
Jampel et al., “In Vitro Release of Hydrophobic Drugs From Polyanhydride Disks,”Ophthalmic Surgery 22(11): 676-680, 1991.
Ike et al., “Biodegradation and antitumor effect of adriamycin-containing poly(L-Lactic acid) microspheres,”Biomaterials 12: 757-762, Oct. 1991.

Affiliated with

Also associated with

Rating

Anti-angiogenic compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-angiogenic compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-angiogenic compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3378217